It is our capability and our commitment that make us GRAIL
We believe we are taking on one of the biggest challenges of our lifetime, combining science, technology, and population-scale clinical studies to reveal cancer at its beginnings.
To detect cancer early, when it can be cured.
Finding a better way
At GRAIL, we find purpose in our mission and call on our passion as we tackle one of the most important problems in the world. Each person at GRAIL plays a vital role in navigating the complexity of our endeavor, and we continuously collaborate because we believe the whole is greater than the sum of its parts. We know that we have the drive, tools, and expertise to not only reach our goals but to accomplish them for the sake of humanity.
Jennifer Cook is Chief Executive Officer of GRAIL. Jennifer also serves on the Board of Directors of Denali Therapeutics. Previously, Jennifer was at Roche Pharmaceuticals/Genentech where she held a number of senior management positions, covering the full lifecycle of product development and commercialization. From 2013 to 2016 she was Head of Region Europe for Roche Pharmaceuticals, where she was responsible for the commercial success of Europe and leading more than 5,500 employees across the 28 countries of the region. Other key positions during her 25-year tenure at Roche/Genentech included leading Global Clinical Operations, US and Global Product Portfolio Management, a US Commercial Business Unit, and Market Development. Jennifer started her career in research and early development at Genentech and a venture-backed start-up company. In 2016, Jennifer was recognized for her contributions to the healthcare industry and inspirational leadership when she was named Woman of the Year by the Healthcare Businesswomen’s Association. Jennifer holds a BA in Human Biology and an MS in Biology from Stanford University, as well as an MBA from the Haas School of Business at University of California, Berkeley.
George Golumbeski is President and Head of Corporate Development and Strategy of GRAIL. George also serves on the Board of Directors of several biotechnology companies, including KSQ Therapeutics, Carrick Therapeutics, Enanta Pharmaceuticals, and MorphoSys. Previously, George was Executive Vice President of Business Development for Celgene, where he was responsible for forging collaborations with biotechnology companies seeking to bring breakthrough medications to people suffering from cancer and chronic inflammation. He holds a PhD in genetics from the University of Wisconsin-Madison, and conducted his post-doctoral research in molecular biology at the University of Colorado-Boulder. George holds a BA in Biology from the University of Virginia.
Alex Aravanis, MD, PhD, is Chief Scientific Officer and Head of R&D, and a Founder of GRAIL. Prior to GRAIL, Alex served as Senior Director of R&D for Illumina, Inc., where he developed multiple products, including clinical assays for the analysis of RNA and DNA from fixed tissues, whole exome analysis, massively parallel single cell transcriptomics and liquid biopsy using cell-free nucleic acids. Additionally, Dr. Aravanis served as Vice President of Development and Chief Science Officer of Sapphire Energy Inc., and was a Co-Founder and Vice President of Engineering of Pria Diagnostics, LLC. Alex holds a BS in Electrical Engineering, Computer Science, and Physics from the University of California, Berkeley, as well as an MS and PhD in Electrical Engineering, and an MD from Stanford University.
Charlotte Arnold is Vice President of Corporate Affairs at GRAIL. Prior to GRAIL, Charlotte was Vice President of Corporate Communications and Investor Relations at Relypsa. Before Relypsa, Charlotte worked at Genentech, where she held several roles including leading communications for Genentech’s portfolio of cancer medicines, and communications regarding policy issues, managed care, pricing, distribution, and access. Charlotte is on the Advisory Board of the San Francisco Bay Area Chapter of the Healthcare Businesswomen’s Association. Charlotte holds a BS in Physiology from the University of Bristol.
Patrick Broderick is General Counsel and Corporate Secretary of GRAIL. Prior to GRAIL, Patrick was General Counsel of McKesson Distribution Solutions at McKesson Corporation where he managed the legal teams supporting all of McKesson’s distribution businesses. Patrick holds a JD from Yale Law School where he was an editor of the Yale Law Journal, and a BA, summa cum laude, from Harvard College.
Onaiza Cadoret-Manier is Chief Commercial Officer of GRAIL. Previously, Onaiza was Vice President of the Respiratory Franchise at Genentech, where she built and managed a team of more than 400 employees responsible for successfully commercializing Genentech’s portfolio of respiratory medicines with revenue of approximately $3 billion. Before that she held various senior management positions overseeing sales and marketing for a number of different products at Genentech, Pfizer, Amylin Pharmaceuticals, and Quest Diagnostics. Onaiza has extensive commercial and operational experience both in the United States and internationally. Onaiza holds an MBA from the University of Chicago and a BA in Economics from Queens College.
Renée Galá is Chief Financial Officer of GRAIL. Renée also serves on the Board of Directors of Corcept Therapeutics, Inc. and Gossamer Bio, Inc. Previously, Renée was Chief Financial Officer of Theravance Biopharma, where she led a variety of functional areas, completed multiple financing transactions, and established an international operating structure for the company, following its spin-out from Theravance, Inc. (now Innoviva, Inc.) in 2014. Renée joined Theravance, Inc. in 2006 and held various roles in the finance organization before leading the Theravance Biopharma spin-out. Before Theravance, Renée worked at Eli Lilly and Company, where she held positions of increasing responsibility in global treasury, pharmaceutical sales, and corporate strategy/business development. Prior to joining Eli Lilly, she spent seven years in the energy industry in the United States and internationally in positions focused on corporate finance, project finance, and mergers and acquisitions. Renée holds a BS in Mathematics from Vanderbilt University and an MBA from Columbia Business School.
Anne-Renee Hartman, MD, is Vice President of Clinical Development at GRAIL. Prior to GRAIL, Anne-Renee was the Senior Vice President of Clinical Development at Myriad Genetics, where she led the development of several commercialized diagnostics in oncology. Anne-Renee was previously an Assistant Professor of Medicine at The Dana Farber Cancer Institute. She completed her oncology fellowship at Stanford where she helped set up the cancer genetics clinic. Anne-Renee holds a BS in Molecular Biology from Princeton University, an MD from The University of Michigan, and completed her residency in Internal Medicine at The University of Chicago.
Fred Kohler is Vice President of People at GRAIL. Prior to GRAIL, Fred worked at Roche/Genentech leading change and agility transformation work globally. Before that, Fred worked at Autodesk and Juniper Networks where he held a wide variety of HR roles in the United States, Europe, and Asia. Fred holds an MBA from University of California, Berkeley and an BA in Economics and English from Bucknell University.
Angela Lai is Chief Technology Officer of GRAIL. Previously, Angela was a Vice President at Google (2004-2016), where she led the Product and Engineering teams that developed Google products including AdWords, Wallet and Payment, and Search. Before Google, Angela founded and ran her own software development company. Angela holds BS degrees in Computer Engineering and Finance, and an MS in Computer Engineering from the University of Pennsylvania.
Elizabeth (Liz) Mansfield, PhD, is Vice President of Regulatory Strategy at GRAIL. Prior to GRAIL, Liz was Deputy Office Director for Personalized Medicine and Director of the Personalized Medicine Staff in the Office of In Vitro Diagnostic Devices (OIVD) in the Center for Devices at the FDA, where she developed a program to address companion and novel diagnostic devices. She also previously served as a Senior Policy Analyst in OIVD, managing policy and scientific issues, and served in other positions at the FDA including Scientific Reviewer and Genetics Expert. Previously at Affymetrix, Liz was the Director of Regulatory Affairs (2004-2006). She holds a PhD from Johns Hopkins University and completed further postdoctoral training at the National Cancer Institute (NCI) and the National Institute for Arthritis, Musculoskeletal, and Skin Diseases (NIAMS).
Jessica Owens is Vice President of Strategy at GRAIL. Prior to GRAIL, Jessica worked with Illumina to create the first business plan for GRAIL and led the spin-out team. Previously at Genomic Health, Jessica worked in Corporate Strategy and was a partner at Kleiner, Perkins, Caufield & Byers (2006-2010). Jessica holds an MBA from Harvard Business School and an MS in Cancer Biology from Stanford University.
Board of Directors
Catherine Friedman is the Chair of the Board of Directors of GRAIL. Catherine is an independent financial consultant who has been serving public and private companies in the life sciences industry since 2006. Previously, Catherine held numerous executive positions during a 23-year investment banking career with Morgan Stanley, including Managing Director, and Head of West Coast Healthcare, and Co-Head of the Biotechnology Practice. Catherine is a member of the Boards of Directors of Altaba (formerly Yahoo!), Radius Health, and Lyell Immunopharma, Inc. She is a trustee of The Darden School Foundation at the University of Virginia. Catherine holds a BA in Economics from Harvard University and an MBA from The University of Virginia’s Darden School of Business.
Jeff Huber is the Founding Chief Executive Officer and Vice Chair of the Board of Directors of GRAIL. Prior to GRAIL, Jeff worked at the intersection of life sciences and computer science at Google[x]. Previously at Google, Jeff led development for Google Ads, Google Apps, and Google Maps. Jeff holds a BS in Computer Engineering from the University of Illinois and an MS from Harvard University. He is a board member of Electronic Arts (EA) and The Exploratorium, and former board member of Illumina (ILMN; 2014-2016).
Hal Barron, MD, is the Chief Scientific Officer and President of R&D at GlaxoSmithKline (GSK). Prior to his role at GSK, Dr. Barron was Calico’s President of R&D. Previously, he was Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Roche Pharmaceuticals. Prior to that, he was Senior Vice President and Chief Medical Officer of Genentech.
Dr. Barron is also Associate Adjunct Professor of Epidemiology and Biostatistics at the University of California, San Francisco. Dr. Barron holds a BA in physics from Washington University in St. Louis and an MD from Yale University.
Hans Bishop is a member of the Board of Directors of Celgene and Agilent Technologies. Mr. Bishop founded Juno Therapeutics in 2013 and served as its President and Chief Executive Officer until the company was acquired by Celgene in 2018.
Prior to this, he served as an Executive in Residence at Warburg Pincus. Earlier, he was Executive Vice President and Chief Operating Officer for Dendreon, Inc. He also previously served as President of Specialty Medicine at Bayer Healthcare, Senior Vice President of Global Commercial Operations at Chiron Corporation, and Vice President and General Manager of European Biopharmaceuticals. Mr. Bishop holds a BA in chemistry from Brunel University in London.
Brook Byers is a founding member and Partner of Kleiner Perkins Caufield & Byers (KPCB). A venture capital investor since 1972, Brook formed the first life sciences practice group in the venture capital profession in 1984 and led KPCB to become a premier venture capital firm in the medical, healthcare, and biotechnology sectors. Brook was the Founding President and then Chairman of four biotechnology companies that were incubated in KPCB’s offices and went on to become public companies with an aggregate market value of more than $8 billion.
In addition to serving on the Board of Directors of Cell Design Labs, Enjoy, Newsela, and Zephyr Health, Brook also serves on the Board of Overseers of the University of California, San Francisco medical campus and hospitals, the Stanford Medicine Advisory Council, and the Board of Directors of the New Schools Foundation. Brook holds a BS in Electrical Engineering from Georgia Institute of Technology and an MBA from Stanford University. In 2010, he received an honorary PhD from Georgia Institute of Technology.
Jennifer Cook is the Chief Executive Officer of GRAIL. Previously, Jennifer was Head of Clinical Operations in Product Development for Roche Pharmaceuticals, where she managed a clinical trial portfolio of more than 400 trials with 100,000 participants. Before that she was Head of Region Europe for Roche Pharmaceuticals, where she was responsible for the commercial success of Europe and leading more than 5,500 employees across the 28 countries of the region. Jennifer started her career at Genentech in early-stage research and subsequently held numerous senior management positions covering the full lifecycle of product development and commercialization. Key positions included leading Product Portfolio Management, a U.S. Commercial Business Unit, and Market Development. In 2016, Jennifer was recognized for her contributions to the healthcare industry and inspirational leadership when she was named Woman of the Year by the Healthcare Businesswomen’s Association. Jennifer holds a BA in Human Biology and MS in Biology from Stanford University, as well as an MBA from the Haas School of Business at University of California, Berkeley.
Min Cui, PhD, is the Founder and Managing Director of Decheng Capital. He is a member of the Board of Directors of AccuraGen, Ariagen, ARMO BioSciences, CardioMed, EpimAb Biotherapeutics, GenapSys, GeneMDx, Ketai Medical, Levitas and SINOMED. Prior to founding Decheng Capital, Min was an investment partner at Bay City Capital and director of Strategic Investment for the Southern Research Institute. Min co-founded Pan Pacific Pharmaceuticals and Hucon Biopharmaceuticals. Min holds a PhD in Cancer Biology from Stanford University and BS and MS degrees in Molecular Biology from Peking University. Min was also a Co-Founder of CNetwork, a San Francisco-based non-profit organization dedicated to serving Chinese communities in North America.
Kaye Foster is a Senior Advisor with Boston Consulting Group (BCG) and sits on the Board of Directors of Agios as well as the Board of Trustees of Spelman College, Stanford Healthcare, and ValleyCare Health System. She previously served as Senior Vice President, Global Human Resources for Onyx Pharmaceuticals, Vice President of Global Human Resources for Johnson & Johnson leading a worldwide team of over 3,000 Human Resources professionals, and as a Human Resources leader at Pfizer across Japan, Asia, Africa, Middle East, and Latin America. Kaye holds a BA from Baruch College and an MBA from Columbia Business School.
George Golumbeski is the President and Head of Corporate Development and Strategy of GRAIL. George also currently serves on the Board of Directors of several biotechnology companies, including KSQ Therapeutics, Carrick Therapeutics, Enanta Pharmaceuticals, and MorphoSys. Previously, George was Executive Vice President of Business Development for Celgene, where he was responsible for forging collaborations with biotechnology companies seeking to bring breakthrough medications to people suffering from cancer and chronic inflammation. He holds a PhD in genetics from the University of Wisconsin-Madison, and conducted his post-doctoral research in molecular biology at the University of Colorado-Boulder. George holds a BA in Biology from the University of Virginia.
Richard (Rick) Klausner, MD, is a Founder of GRAIL. Rick is CEO of Lyell Immunopharma, Executive Chair of Mindstrong Health, and Chair of Medical Creations, Wisdo, and LifeMine.
Rick was a Founder and Director of Juno Therapeutics until its acquisition by Celgene in 2018. He is the former Senior Vice President, Chief Medical Officer and Chief Opportunity Officer of Illumina and former Executive Chairman of Audax Health. Previously, he served as Managing Partner of the Venture Capital firm, The Column Group, and was the Executive Director for Global Health of the Bill and Melinda Gates Foundation. Rick was appointed by Presidents Clinton and Bush as the eleventh Director of the U.S. National Cancer Institute between 1995 and 2001. He also served as Chief of the Cell Biology and Metabolism Branch of the National Institute of Child Health and Human Development, as well as a past president of the American Society of Clinical Investigation. He is a Fellow of the AACR Academy. Rick holds an MD from Duke Medical School.
Robert Nelsen is a Co-Founder and a Managing Director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the early sourcing, financing and development of more than 30 companies, including 15 which have reached valuations exceeding $1 billion. His seed and early-stage investments include Illumina (ILMN); Alnylam Pharmaceuticals (ALNY); Juno Therapeutics (JUNO); Agios Pharmaceuticals (AGIO); Sage Therapeutics (SAGE); Ikaria; Kythera Biopharmaceuticals (KYTH), Receptos (RCPT); Aviron (AVIR); Denali Therapeutics; NetBot; Bluebird Bio (BLUE); R2 Technology; XenoPort (XNPT); Caliper Life Sciences (CALP); Trubion Pharmaceuticals (TRBN); Adolor (ADLR); deCODE Genetics; Array BioPharma (ARRY); IDUN Pharmaceuticals; Classmates.com; Hua Medicine; Fate Therapeutics (FATE); NextCODE Health; and Everyday Learning Corporation.
Robert is a Director of Agios Pharmaceuticals, Denali Therapeutics, Sage Therapeutics, Arivale, Syros Pharmaceuticals, and serves as Chairman of Hua Medicine, among others. He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute for Systems Biology, and as a Director of the National Venture Capital Association. Robert holds a BS in Economics and Biology from University of Puget Sound and an MBA from the University of Chicago.
Bill Rastetter, PhD, is the Chairman for Neurocrine Biosciences and Fate Therapeutics, a board member for Regulus, Caltech and Daré, and an advisor to Leerink Partners and Illumina Ventures. Bill was a Founder and Chairman of Receptos, which sold to Celgene in 2015. Bill led the merger of equals that formed Biogen Idec in 2003, and retired as Executive Chairman at the end of 2005. He joined Idec Pharmaceuticals at its founding in 1986 and grew it to a multi-billion dollar market valuation company while serving as Chairman and Chief Executive Officer. While at Idec, Bill was a co-inventor of Rituxan®, which became the first monoclonal antibody approved by the U.S. Food and Drug Administration for cancer and one of the world’s most valuable cancer therapies.
Prior to Idec, Bill served in various capacities at Genentech. Previously, he held faculty positions at Massachusetts Institute of Technology, won the award for “Excellence in the Teaching of Chemistry” at Harvard, and was named an Alfred P. Sloan Fellow. Bill holds a BS in Chemistry from the Massachusetts Institute of Technology and a PhD in Chemistry from Harvard University.
Scientific Advisory Board
Vikram (Vik) Bajaj, PhD, is a Managing Director at Foresite Capital. Previously, Dr. Bajaj was Chief Scientific Officer of GRAIL, where he led laboratory and data science teams at the forefront of industrial cancer genomics and diagnostics development. He is the Co-Founder and former Chief Scientific Officer of Verily (formerly Google Life Sciences) and serves as the Chair of Verily’s Scientific Advisory Board. Prior to joining Google, Dr. Bajaj was a principal investigator at the University of California, Berkeley, and the Lawrence Berkeley National Laboratory. He retains academic appointments as Associate Professor (consulting) at the Stanford School of Medicine, and as an Affiliate Scientist of the Lawrence Berkeley National Laboratory and the University of California, Berkeley, for which he serves on the advisory board of the College of Chemistry. Dr. Bajaj’s research interests lie at the interface of the physical sciences, engineering, and the life sciences. Aspects of this work have been commercialized through Agenea Sciences, SkinScan, and Verily. He holds a PhD in Biochemistry and Physical Chemistry from the Massachusetts Institute of Technology.
Donald Berry, PhD, is Professor and Founding Chair of the Department of Biostatistics of the University of Texas MD Anderson Cancer Center. Dr. Berry previously served on the faculties of the University of Minnesota and Duke University. He has held endowed faculty positions at Duke University and at MD Anderson. He has designed and supervised the conduct of many large clinical trials. A principal focus of his research is the use of biomarkers in cancer and other diseases for learning which patients benefit from which therapies, based on genomics and phenotype. In particular, Dr. Berry has designed and is a co-primary investigator of I-SPY 2 www.ispy2.org and GBM AGILE nbdabiomarkers.org/gbm-agile, Bayesian adaptive platform clinical trials in high-risk early breast cancer and glioblastoma multiforme, respectively, whose goals are matching experimental therapies with patient subsets defined by tumor molecular characteristics. Through Berry Consultants, LLC he has designed many innovative clinical trials in all therapeutic areas for pharmaceutical and medical device companies and for international consortia. Dr. Berry is the author of books on statistical methodology and over 400 published articles. He serves on the PDQ Screening and Prevention Board of the National Cancer Institute for which he received the National Institutes of Health Award of Merit in 2010. In 2014 he was named a Thomson Reuters Highly Cited Researcher in Clinical Medicine and listed as one of The World’s Most Influential Scientific Minds in ScienceWatch.com. Dr. Berry has been the principal investigator for numerous research grants from the National Institutes of Health and the National Science Foundation. He is a Fellow of the American Statistical Association and the Institute of Mathematical Statistics. Dr. Berry holds a PhD in Statistics from Yale University.
Timothy Church, PhD, is a Professor in the Division of Environmental Health Sciences in the School of Public Health at the University of Minnesota. His expertise is in cancer screening, colorectal cancer, medical device evaluation, biostatistics, epidemiologic methods, and clinical trial design. Dr. Church is currently leading multiple trials and studies regarding colorectal, prostate, lung, and ovarian cancer, and has recently established a registry for Parkinson’s Disease research. His primary research interests include clinical trials and epidemiological studies related to screening for and prevention of multiple cancers, as well as the development of biostatistical and epidemiologic methods. He teaches Occupational and Environmental Epidemiology and a doctoral seminar on causal inference. Dr. Church holds a PhD and MS in Biometry and Health Information Systems from the University of Minnesota.
Christina Curtis, PhD, is an Assistant Professor of Medicine (Oncology) and Genetics at Stanford University School of Medicine, where she leads the Cancer Computational and Systems Biology Group. She also serves as Co-Director of the Molecular Tumor Board at the Stanford Cancer Institute. Leveraging genome-scale data, Dr. Curtis’ research focuses on experimental and computational approaches to improve the diagnosis, treatment, and early detection of cancer. Her research has redefined the molecular map of breast cancer and led to new paradigms in understanding how tumors evolve. Among numerous distinguished honors throughout her career, Dr. Curtis is the recipient of the 2012 V Scholar Award from the V Foundation for Cancer Research, 2012 Career Development Award from STOP Cancer, 2016 Career Development Award from the American Association for Cancer Research (AACR), and was named a National Academy of Science (NAS) Kavli Frontier of Science fellow in 2016. She holds a PhD in Molecular Biology from the University of Southern California and was a postdoctoral fellow in Computational Biology at the University of Cambridge.
Jeff Dean, PhD, joined Google in 1999 and is currently a Google Senior Fellow in Google’s Research Group, where he leads the Google Brain team, Google’s deep learning research team, working on systems for speech recognition, computer vision, language understanding, and various predictive tasks. He has co-designed and implemented five generations of Google’s crawling, indexing, and query serving systems, and co-designed and implemented major pieces of Google’s initial advertising and AdSense for Content systems. He is also a co-designer and co-implementor of Google’s distributed computing infrastructure, including the MapReduce, BigTable and Spanner systems, protocol buffers, LevelDB, and TensorFlow, a popular open-source system for machine learning.
Dr. Dean is a Fellow of the ACM, a member of the U.S. National Academy of Engineering and the American Academy of Arts and Sciences, and a recipient of the Mark Weiser Award and the ACM-Infosys Foundation Award in the Computing Sciences. He holds a PhD in Computer Science from the University of Washington in 1996.
Brian Druker, MD, is Director of the Oregon Health & Science University (OHSU) Knight Cancer Institute, JELD-WEN Chair of Leukemia Research, OHSU, and an Investigator of the Howard Hughes Medical Institute. After training in oncology at Harvard University’s Dana-Farber Cancer Institute, Dr. Druker returned to the lab to study the regulation of the growth of cancer cells and its application to cancer therapies. His work was instrumental in the development of imatinib (Gleevec), a drug that targets the molecular defect in chronic myeloid leukemia. After completing a series of preclinical studies, Dr. Druker planned and led the highly successful clinical trials of imatinib for CML. Imatinib is FDA-approved for CML, gastrointestinal stromal tumors and eight other tumors. His role in the development of imatinib and its application in the clinic have resulted in numerous awards for Dr. Druker, including the Warren Alpert Prize from Harvard Medical School, the Kettering Prize from General Motors Cancer Research Foundation, the 2009 Lasker-DeBakey Award for Clinical Medical Research and the Japan Prize in Healthcare and Medical Technology. He was elected to the National Academy of Medicine in 2003, the American Association of Physicians in 2006, the National Academy of Sciences in 2007, and the American Academy of Arts and Sciences in 2012.
Sanjiv Gambhir, MD, PhD, is the Virginia & D.K. Ludwig Professor of Cancer Research, Chairman of Radiology at Stanford University School of Medicine, and heads the Canary Center for Cancer Early Detection at Stanford University. Dr. Gambhir has more than 570 publications in the field and more than 40 patents pending or granted. He is an internationally recognized researcher in molecular imaging with over $90 million of NIH funding as the Principal Investigator. His lab has focused on interrogating fundamental molecular events in living subjects. He has developed and clinically translated several multimodality molecular imaging strategies including imaging of gene and cell therapies. Dr. Gambhir was elected to the National Academy of Medicine in 2008 and to the Academy of Inventors in 2015. He holds an MD and a PhD from the University of California, Los Angeles.
William N. Hait, MD, PhD, is Global Head, External Innovation at Johnson & Johnson. Previously, he was Head of Global Research and Development for the Janssen Pharmaceutical Companies of Johnson & Johnson. Before joining Johnson & Johnson in 2007, he was the founding Director of The (Rutgers) Cancer Institute of New Jersey. From 1993 to 2007 he was Professor of Medicine and Pharmacology and Associate Dean for Oncology Programs at the University of Medicine and Dentistry of New Jersey — Robert Wood Johnson Medical School. Before that, Dr. Hait was Associate Professor of Medicine and Pharmacology, Chief of the Division of Medical Oncology, Associate Director of the Yale University Comprehensive Cancer Center, Director of the Breast Cancer Unit, and Co-Director of the Lung Cancer Unit.
Dr. Hait is past President of the American Association for Cancer Research (AACR) and currently serves as Treasurer. He has served on various committees for the AACR, the American Society of Clinical Oncology (ASCO), the Association of American Cancer Institutes, the National Cancer Institute Board of Scientific Advisors, and was founding Chairman of the Executive Management Committee of Stand Up to Cancer. He currently is a member of the Rutgers Cancer Institute of New Jersey Director’s Advisory Board, Board of External Advisors for the Dana Farber/Harvard Cancer Center, the Stand Up to Cancer Scientific Advisory Board, The Board of Directors of Research!America, and the Vanderbilt University Biomedical Science Advisory Board. Dr. Hait holds a BA from the University of Pennsylvania. He holds an MD and a PhD from the Medical College of Pennsylvania.
Richard (Rick) Klausner, MD, is Founder and Director of Juno Therapeutics and Executive Chairman of Wisdo, a third generation internet company. He is the Chairman of Mindstrong and a Director of AnchorDx. He currently Chairs the Grand Challenges in Cancer program of Cancer Research UK.
Dr. Klausner is the former Senior Vice President, Chief Medical Officer and Chief Opportunity Officer of Illumina. He is the former Executive Chairman of Audax Health. Previously, he served as Managing Partner of the Venture Capital firm, The Column Group, and was the Executive Director for Global Health of the Bill and Melinda Gates Foundation. Dr. Klausner was appointed by Presidents Clinton and Bush as the eleventh Director of the U.S. National Cancer Institute between 1995 and 2001. He also served as chief of the Cell Biology and Metabolism Branch of the National Institute of Child Health and Human Development, as well as a past president of the American Society of Clinical Investigation. Dr. Klausner holds an MD from Duke Medical School.
Dennis Lo, MD, PhD, is the Director of the Li Ka Shing Institute of Health Sciences, the Li Ka Shing Professor of Medicine, and Professor of Chemical Pathology at The Chinese University of Hong Kong (CUHK). Dr. Lo was the first scientist to discover the presence of circulating fetal DNA in a pregnant mother’s blood plasma and is a key driver of noninvasive prenatal testing (NIPT). He sees parallels between the release of DNA from a fetus into the bloodstream of its mother and the release of DNA from a tumor into the bloodstream of a cancer patient. Over the last 20 years, he has made many original discoveries on the biological characteristics of circulating fetal and tumor DNA, and has developed many innovative technologies for plasma nucleic acids-based molecular diagnostics. Dr. Lo has been recognized with numerous prestigious awards and honors for his contributions, including the 2016 Future Science Prize in Life Sciences. He was elected as a Fellow of the Royal Society (FRS) in 2011 and as a Foreign Associate of the US National Academy of Sciences in 2013. Dr. Lo holds a BA from the University of Cambridge, and holds an MD and a PhD from the University of Oxford.
Franz Och, PhD, is an expert in machine learning, artificial intelligence, large-scale data processing, and data analysis, specifically in the areas of natural language processing, machine translation, and genomics. He was most recently the Head of Data Science at GRAIL. Prior to GRAIL, Dr. Och was the Chief Data Scientist at Human Longevity, Inc where he worked on large-scale applications of whole genome sequencing. Previously at Google, he was a Distinguished Research Scientist and credited as chief architect of Google Translate. He holds a PhD in Computer Science from RWTH Aachen University.
Michael Stratton, PhD, is Director of the Wellcome Trust Sanger Institute. His primary research interests have been in the genetics of cancer. His early research focused on inherited susceptibility. He mapped and identified the major high risk breast cancer susceptibility gene BRCA2 and subsequently a series of moderate risk breast cancer and other cancer susceptibility genes.
In 2000, Sir Stratton initiated the Cancer Genome Project at the Wellcome Trust Sanger Institute which conducts systematic genome-wide searches for somatic mutations in human cancer. Through these studies he discovered somatic mutations of the BRAF gene in malignant melanoma and several other mutated cancer genes in lung, renal, breast and other cancers. He has described the basic patterns of somatic mutation in cancer genomes revealing underlying DNA mutational and repair processes.
Sir Stratton holds a PhD from the University of Oxford. He is a Fellow of the Royal Society (FRS) and was Knighted by Queen Elizabeth II in 2013.
Charles Swanton, MD, PhD, is Senior Clinical Research Fellow at Cancer Research UK (CRUK) and Group Leader of the Translational Cancer Therapeutics laboratory at the London Research Institute. He combines his laboratory research with clinical duties focused on biological mechanisms of cancer drug resistance. Dr. Swanton is a Fellow of the Royal College of Physicians and Chair in Personalized Cancer Medicine and Consultant Thoracic Medical Oncologist at University College London Hospitals (UCLH). Dr. Swanton is the Chief Investigator of the CRUK TRACERx lung cancer evolution study and is Director of the CRUK/UCL Lung Cancer Centre of Excellence. In 2013, he was awarded the Royal College of Physicians Goulstonian lecture and Graham Bull Prize for Clinical Sciences, and was appointed Fellow of the European Academy of Cancer Sciences. Dr. Swanton holds an MD and a PhD from the Imperial Cancer Research Fund Laboratories.
Karen Vousden, PhD, is the Chief Scientist of Cancer Research UK, responsible for overseeing the organization’s scientific research. She also leads a research group focused on understanding the regulation and functions of the p53 tumour suppressor protein, with an increasing emphasis on how changes in metabolism can influence cancer development. Her work has led to several possible clinical applications, including the development of small molecule activators of p53 that prevent the proteolytic degradation of the protein, and the potential of amino acid limited diets to augment standard chemotherapeutic approaches to treatment.
Dr. Vousden has been elected as a Fellow of the Royal Society (FRS), the Royal Society of Edinburgh, EMBO, the Academy of Medical Sciences, the European Academy of Sciences, the American Association for the Advancement of Science, and the American Academy for Arts & Sciences. Dr. Vousden holds a PhD in Genetics from the University of London and received postdoctoral fellowships with Chris Marshall at the Institute of Cancer Research in London and Douglas Lowy at the National Cancer Institute. She received honorary DScs from the Universities of London and Strathclyde.